Articles related to PTSD

A Phase 2B study found that a 25mg dose of psilocybin, combined with psychotherapy, produced a significant drop in patients’ scores on the Montgomery Asberg Depression Rating Scale (MADRS) after 12 weeks. This finding underscores the potential of psilocybin-assisted therapy as a promising treatment for depression.

This double-blind, placebo-controlled trial suggests that topiramate monotherapy may be an effective treatment for civilian PTSD. Despite the decrease in total CAPS score not being statistically significant, topiramate-treated patients exhibited significant reductions in reexperiencing symptoms.

The recent study on topiramate’s potential role in PTSD treatment has shown that three times as many patients taking topiramate saw their PTSD symptoms decrease below the clinical threshold compared to those on placebo.

Discover how MDMA-assisted therapy is setting new benchmarks in PTSD treatment, offering clinically meaningful improvements and a strong safety profile.

This 22-year study provides a detailed examination of the relationship between antihypertensive medications and PTSD incidence in trauma victims. Physicians interested in the potential preventive role of these medications in PTSD are invited to delve into the findings and implications for future research.

Recent phase 3 clinical trials have demonstrated the eye-opening potential of MDMA in the treatment of PTSD when paired with psychotherapy, providing a new method of patient care.